Truvestments Capital LLC Cyma Bay Therapeutics, Inc. Transaction History

Truvestments Capital LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$5.88 - $9.59 $158 - $258	-27 Reduced 1.94%	1,364 $11,000
Q4 2022 Feb 13, 2023	SELL	$3.22 - $6.27 $309 - $601	-96 Reduced 6.46%	1,391 $8,000
Q2 2022 Aug 09, 2022	BUY	$1.72 - $3.39 $2,557 - $5,040	1,487 New	1,487 $4,000
Q1 2022 May 02, 2022	SELL	$2.77 - $3.64 $2,013 - $2,646	-727 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$4.23 - $6.55 $1,725 - $2,672	408 Added 127.9%	727 $3,000
Q4 2020 Feb 17, 2021	BUY	$5.73 - $9.03 $1,827 - $2,880	319 New	319 $1,000
Q3 2020 Nov 13, 2020	SELL	$3.32 - $7.24 $1,059 - $2,309	-319 Closed	0 $0
Q2 2020 Aug 06, 2020	BUY	$1.41 - $4.25 $449 - $1,355	319 New	319 $1,000
Q4 2019 Jan 29, 2020	SELL	$1.33 - $5.93 $742 - $3,308	-558 Closed	0 $0
Q3 2019 Oct 10, 2019	SELL	$5.12 - $7.21 $327 - $461	-64 Reduced 10.29%	558 $3,000
Q1 2019 Apr 12, 2019	SELL	$8.16 - $13.42 $130 - $214	-16 Reduced 2.51%	622 $8,000
Q3 2018 Oct 22, 2018	BUY	$10.88 - $14.52 $6,941 - $9,263	638 New	638 $7,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Truvestments Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Truvestments Capital LLC with notifications on news.